Azerbaijan

Azerbaijan

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
3.22 (2.79 - 3.63) 2019 Modelled IHME
3.27 (2.85 - 3.71) 2018 Modelled IHME
3.3 (2.86 - 3.87) 2017 Modelled IHME
3.31 (2.87 - 3.85) 2016 Modelled IHME
3.32 (2.85 - 3.86) 2015 Modelled IHME
3.34 (2.87 - 3.87) 2014 Modelled IHME
3.4 (2.92 - 3.92) 2013 Modelled IHME
3.47 (2.97 - 4.01) 2012 Modelled IHME
3.54 (3.04 - 4.11) 2011 Modelled IHME
3.62 (3.06 - 4.21) 2010 Modelled IHME
3.71 (3.17 - 4.29) 2009 Modelled IHME
3.82 (3.28 - 4.40) 2008 Modelled IHME
3.93 (3.37 - 4.51) 2007 Modelled IHME
4.02 (3.44 - 4.60) 2006 Modelled IHME
4.05 (3.45 - 4.66) 2005 Modelled IHME
4.04 (3.43 - 4.61) 2004 Modelled IHME
3.99 (3.42 - 4.55) 2003 Modelled IHME
3.94 (3.35 - 4.50) 2002 Modelled IHME
3.89 (3.29 - 4.47) 2001 Modelled IHME
3.87 (3.27 - 4.45) 2000 Modelled IHME
3.91 (3.31 - 4.49) 1999 Modelled IHME
3.99 (3.39 - 4.56) 1998 Modelled IHME
4.1 (3.47 - 4.70) 1997 Modelled IHME
4.19 (3.53 - 4.85) 1996 Modelled IHME
4.22 (3.55 - 4.96) 1995 Modelled IHME
4.21 (3.55 - 4.93) 1994 Modelled IHME
4.17 (3.53 - 4.86) 1993 Modelled IHME
4.11 (3.48 - 4.74) 1992 Modelled IHME
4.02 (3.41 - 4.63) 1991 Modelled IHME
3.9 (3.31 - 4.48) 1990 Modelled IHME
2.21 (1.26 - 3.54) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.56 (0.41 - 0.72) 2019 Modelled IHME
0.6 (0.44 - 0.77) 2018 Modelled IHME
0.62 (0.45 - 0.80) 2017 Modelled IHME
0.6 (0.44 - 0.77) 2016 Modelled IHME
0.59 (0.42 - 0.75) 2015 Modelled IHME
0.6 (0.44 - 0.77) 2014 Modelled IHME
0.64 (0.47 - 0.82) 2013 Modelled IHME
0.71 (0.53 - 0.90) 2012 Modelled IHME
0.79 (0.58 - 1.01) 2011 Modelled IHME
0.88 (0.65 - 1.13) 2010 Modelled IHME
1.03 (0.76 - 1.31) 2009 Modelled IHME
1.26 (0.92 - 1.62) 2008 Modelled IHME
1.54 (1.11 - 1.97) 2007 Modelled IHME
1.8 (1.30 - 2.32) 2006 Modelled IHME
2.01 (1.44 - 2.58) 2005 Modelled IHME
2.16 (1.56 - 2.75) 2004 Modelled IHME
2.29 (1.68 - 2.89) 2003 Modelled IHME
2.41 (1.78 - 3.04) 2002 Modelled IHME
2.52 (1.86 - 3.19) 2001 Modelled IHME
2.62 (1.93 - 3.37) 2000 Modelled IHME
2.74 (1.98 - 3.48) 1999 Modelled IHME
2.85 (2.05 - 3.62) 1998 Modelled IHME
2.96 (2.08 - 3.74) 1997 Modelled IHME
3.04 (2.09 - 3.88) 1996 Modelled IHME
3.07 (2.10 - 3.99) 1995 Modelled IHME
3.05 (2.11 - 3.93) 1994 Modelled IHME
3 (2.12 - 3.81) 1993 Modelled IHME
2.92 (2.09 - 3.71) 1992 Modelled IHME
2.8 (2.04 - 3.57) 1991 Modelled IHME
2.65 (1.97 - 3.37) 1990 Modelled IHME
0.27 (0.13 - 0.50) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
25 (18 - 34) 2019 Modelled IHME
25 (18 - 34) 2018 Modelled IHME
25 (19 - 34) 2017 Modelled IHME
26 (19 - 34) 2016 Modelled IHME
26 (19 - 35) 2015 Modelled IHME
26 (19 - 35) 2014 Modelled IHME
26 (19 - 35) 2013 Modelled IHME
27 (20 - 36) 2012 Modelled IHME
27 (20 - 36) 2011 Modelled IHME
27 (20 - 36) 2010 Modelled IHME
27 (20 - 36) 2009 Modelled IHME
27 (20 - 36) 2008 Modelled IHME
27 (20 - 35) 2007 Modelled IHME
27 (20 - 35) 2006 Modelled IHME
26 (19 - 35) 2005 Modelled IHME
26 (19 - 35) 2004 Modelled IHME
26 (19 - 35) 2003 Modelled IHME
26 (19 - 35) 2002 Modelled IHME
26 (19 - 35) 2001 Modelled IHME
26 (19 - 34) 2000 Modelled IHME
25 (18 - 34) 1999 Modelled IHME
25 (18 - 34) 1998 Modelled IHME
25 (18 - 34) 1997 Modelled IHME
25 (18 - 33) 1996 Modelled IHME
24 (18 - 33) 1995 Modelled IHME
24 (18 - 32) 1994 Modelled IHME
24 (18 - 32) 1993 Modelled IHME
24 (18 - 32) 1992 Modelled IHME
24 (17 - 31) 1991 Modelled IHME
23 (17 - 31) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
98 2010 Survey/reported WHO/UNICEF
95 2009 Survey/reported WHO/UNICEF
92 2008 Survey/reported WHO/UNICEF
88 2007 Survey/reported WHO/UNICEF
86 2006 Survey/reported WHO/UNICEF
82 2005 Survey/reported WHO/UNICEF
82 2004 Survey/reported WHO/UNICEF
83 2003 Survey/reported WHO/UNICEF
82 2002 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
95 2018 Survey/reported WHO/UNICEF
95 2017 Survey/reported WHO/UNICEF
97 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
94 2014 Survey/reported WHO/UNICEF
93 2013 Survey/reported WHO/UNICEF
88 2012 Survey/reported WHO/UNICEF
84 2011 Survey/reported WHO/UNICEF
80 2010 Survey/reported WHO/UNICEF
74 2009 Survey/reported WHO/UNICEF
68 2008 Survey/reported WHO/UNICEF
62 2007 Survey/reported WHO/UNICEF
52 2006 Survey/reported WHO/UNICEF
49 2005 Survey/reported WHO/UNICEF
50 2004 Survey/reported WHO/UNICEF
51 2003 Survey/reported WHO/UNICEF
50 2002 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
18 (15 - 22) 2014 Survey/reported Republic of Azerbaijan, 2014; Burrows D et al, 2014
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.41 (2.75 - 4.22) 2019 Modelled IHME
3.39 (2.73 - 4.19) 2018 Modelled IHME
3.36 (2.69 - 4.13) 2017 Modelled IHME
3.27 (2.65 - 4.01) 2016 Modelled IHME
3.21 (2.58 - 3.94) 2015 Modelled IHME
3.21 (2.59 - 3.94) 2014 Modelled IHME
3.22 (2.61 - 3.94) 2013 Modelled IHME
3.23 (2.61 - 3.95) 2012 Modelled IHME
3.25 (2.63 - 3.98) 2011 Modelled IHME
3.27 (2.65 - 4) 2010 Modelled IHME
3.32 (2.71 - 4.03) 2009 Modelled IHME
3.41 (2.80 - 4.12) 2008 Modelled IHME
3.52 (2.90 - 4.23) 2007 Modelled IHME
3.62 (2.98 - 4.35) 2006 Modelled IHME
3.7 (3.02 - 4.46) 2005 Modelled IHME
3.76 (3.07 - 4.53) 2004 Modelled IHME
3.82 (3.12 - 4.61) 2003 Modelled IHME
3.87 (3.16 - 4.69) 2002 Modelled IHME
3.9 (3.15 - 4.74) 2001 Modelled IHME
3.92 (3.15 - 4.80) 2000 Modelled IHME
3.86 (3.08 - 4.72) 1999 Modelled IHME
3.71 (3 - 4.54) 1998 Modelled IHME
3.54 (2.85 - 4.37) 1997 Modelled IHME
3.38 (2.70 - 4.19) 1996 Modelled IHME
3.29 (2.62 - 4.09) 1995 Modelled IHME
3.26 (2.62 - 4.05) 1994 Modelled IHME
3.24 (2.60 - 4) 1993 Modelled IHME
3.22 (2.60 - 3.97) 1992 Modelled IHME
3.2 (2.59 - 3.93) 1991 Modelled IHME
3.2 (2.57 - 3.93) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
3.1 (1 - 6.70) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
62.1 (47.10 - 77.20) 2012 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
35 (26 - 45) 2019 Modelled IHME
35 (26 - 45) 2018 Modelled IHME
35 (26 - 45) 2017 Modelled IHME
36 (27 - 45) 2016 Modelled IHME
36 (27 - 45) 2015 Modelled IHME
36 (27 - 45) 2014 Modelled IHME
36 (27 - 45) 2013 Modelled IHME
36 (27 - 45) 2012 Modelled IHME
36 (27 - 45) 2011 Modelled IHME
36 (27 - 45) 2010 Modelled IHME
36 (27 - 45) 2009 Modelled IHME
37 (27 - 46) 2008 Modelled IHME
37 (27 - 46) 2007 Modelled IHME
37 (28 - 47) 2006 Modelled IHME
38 (28 - 47) 2005 Modelled IHME
38 (28 - 47) 2004 Modelled IHME
38 (28 - 47) 2003 Modelled IHME
38 (28 - 47) 2002 Modelled IHME
38 (28 - 47) 2001 Modelled IHME
38 (28 - 47) 2000 Modelled IHME
37 (28 - 47) 1999 Modelled IHME
37 (28 - 46) 1998 Modelled IHME
36 (27 - 45) 1997 Modelled IHME
36 (27 - 45) 1996 Modelled IHME
36 (27 - 44) 1995 Modelled IHME
36 (27 - 44) 1994 Modelled IHME
35 (27 - 44) 1993 Modelled IHME
35 (27 - 43) 1992 Modelled IHME
35 (27 - 43) 1991 Modelled IHME
35 (27 - 43) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (15 - 22) 2014 Survey/reported Republic of Azerbaijan, 2014; Burrows D et al, 2014
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2002
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Many (31-60%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
3.22 (%)
2019
(2.79 - 3.63(%))
IHME
HCV (RNA/cAg+)
3.41 (%)
2019
(2.75 - 4.22(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
698
2019
(497 - 959)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
732
2019
(536 - 1,019)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.56 (%)
2019, latest modelled
(0.41 - 0.72(%))
IHME

Prevalence PWID

HCV
62.10 (%)
2012, latest modelled
(47.10 - 77.20(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
99 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
18
2014
(15 - 22)
Republic of Azerbaijan, 2014; Burrows D et al, 2014
Eligible for HBV generic medicines
Eligible for HCV generic medicines